Nuvalent, Inc. is a biopharmaceutical company focused on developing therapies for cancer patients. Their lead product candidates, NVL-520 and NVL-655, are brain-penetrant inhibitors designed to address treatment resistance and adverse events associated with current inhibitors. NVL-520 targets ROS1 fusions, while NVL-655 targets ALK. Both candidates are currently in Phase I/II clinical trials. The company was founded in 2017 and is based in Cambridge, Massachusetts.